Investors

To be an investor you must be a believer in a better tomorrow ~ Benjamin Graham

Hemera is a biotech company and an innovative start-up born with the aim of transforming scientific findings in the field of neuroregeneration into effective treatments, to bring research results to the patient bedside as soon as possible.

Hemera’s goal is to develop REMAST cell therapy as an advanced pharmacological product for the treatment of neurological lesions, transferring the therapy for spinal cord lesions conceived in the laboratories of the Universities of Verona and Milan into clinical practice.

Our ROADMAP

  • 2021

    2021

    2022

    2023

    2024

    2025

    2026

    Milestones

    2021

    • Filing of the Italian patent application
    • Foundation of the company
    • Recognition as a spin-off of the Universities of Verona and Milan
    • Constitution of the Regulatory & Advisory Board
    • Initial selection of strategic partnerships
    • Capital raising: 750,000 euros
  • 2022

    2021

    2022

    2023

    2024

    2025

    2026

    Milestones

    2022

    • International extension of the patent application
    • Selection of the therapy’s route of administration
    • Activation of a network of neurosurgery and neurorehabilitation facilities
    • Constitution of the Clinical board
    • EMA Advanced therapy medicinal product (ATMP) designation
    • Design of the protocol for the prospective observational study
    • Organizational development (operative directions)
    • Conduction of the first production tests of the therapy for clinical use
    • Capital raising: 1.5 million euros
  • 2023

    2021

    2022

    2023

    2024

    2025

    2026

    Milestones

    2023

    • Granting of the Italian patent
    • EMA Orphan Drug Designation Application
    • Testing of the therapy administration technique
    • Patent application in individual countries
    • Scientific publication on high-impact journals
    • Enrolment of 15 patients in a prospective observational study
    • Production of the cell therapy in a closed loop system
    • Fundraising
  • 2024

    2021

    2022

    2023

    2024

    2025

    2026

    Milestones

    2024

    • Monitoring of 15 patients in the prospective observational study
    • Final production protocol of the cell therapy for clinical use
    • Design of the protocol for the interventional clinical trial
    • Fundraising
  • 2025

    2021

    2022

    2023

    2024

    2025

    2026

    Milestones

    2025

    • Start of the multicenter interventional Phase 1-2 Clinical Trial
    • Fundraising
    • Validation of the therapy optimal dose, safety, and efficacy on the first patients
  • 2026

    2021

    2022

    2023

    2024

    2025

    2026

    Milestones

    2026

    • Multicenter interventional Phase 1-2 Clinical Trial
    • Monitoring of safety and efficacy of the therapy
    • Start of the PRIME program
    • Early exit scenario

Fundraising according to Hemera

A new democratic form of investment aimed at raising the required capital from anyone who is interested in the development of new therapies for very disabling diseases and is looking for a truly socially responsible investment.

Since its foundation, in May 2021, the company has raised over 2 million euros.

In the first 18 months of the company’s life, 1 Family Office and over 100 business angels, private investors, and companies – who organized themselves into two investment syndicates called Friends of Founders S.r.l. and Proemera S.r.l. – invested in Hemera.